Trial Profile
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 30 Nov 2021 The primary endpoints have been changed from Crohn's Disease Activity Index, Harvey Bradshaw Index, Adverse events, and Change in laboratory parameters to Number of Participants With Treatment-emergent Adverse Events, Percentage of Participants Who Achieved a CDAI Response, Percentage of Participants Who Achieved Clinical Remission, according to ClinicalTrials.gov record.
- 24 May 2014 New trial record